Latest Regulatory News

Structural Monitoring Systems Plc (SMS) reported a breakout second half of FY25 with a $3.1 million profit after tax, driven by strong operational leverage and strategic growth in avionics. The company secured over US$1 million in new orders from CAL FIRE and advanced FAA certification for its innovative sensor technology.

PointsBet has firmly dismissed Betr Entertainment’s unsolicited scrip takeover proposal, endorsing instead MIXI Australia’s superior all-cash offer. The board highlights significant risks and uncertainties tied to Betr’s bid while unanimously recommending shareholders accept MIXI’s $1.20 per share offer.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Generation Development Group reports a transformative FY25 with record Investment Bond sales and successful integration of Evidentia and Lonsec managed accounts, setting the stage for strong growth in FY26.

Miramar Resources has announced a $1 million Share Purchase Plan to fast-track drilling at its promising 8 Mile gold prospect near Kalgoorlie, following recent significant mineralisation discoveries.

Condor Energy has secured a 12-month extension for its Technical Evaluation Agreement in Peru’s Tumbes Basin, underpinning its exploration and commercialisation plans backed by significant prospective oil and gas resources.

Aurum Resources reports strong high-grade drilling results at its Boundiali and Napié gold projects, backed by a $35.6 million strategic placement to fund resource expansion and feasibility studies.

MAC Copper Limited has scheduled a key court hearing on July 30 to progress Harmony Gold’s recommended acquisition, moving closer to shareholder votes and regulatory approvals.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.

Hutchison Telecommunications (Australia) Limited has been suspended from ASX trading following compulsory acquisition notices issued by its Amsterdam-based parent company.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.